Claims:

1. A pharmaceutical composition, comprising: a compound of formula (1) in solid form:

together with a pharmaceutically acceptable carrier or excipient,

provided that the compound of formula (1) is present in polymorphic Form A and is substantially free of other polymorphic forms.

- 2. The composition of claim 1 in which the compound of formula (1) is present as orthorhombic crystals.
- 3. The composition of claim 1, which is in the form of a tablet or capsule.
- 4. The tablet or capsule of claim 3, which gives rise to a PXRD pattern substantially as shown for polymorphic Form A in Figure 6.
- 5. The composition of claim 1, wherein at least about 90% of the compound of formula (1) is polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.
- 6. The composition of claim 1, further comprising lactose and microcrystalline cellulose.
- 7. The tablet of claim 3, which weighs between 250 and 500 mg.
- 8. A composition comprising isolated crystals of the compound of formula (1)

in which the isolated crystals of compound (1) are present in polymorphic Form A and substantially free of other polymorphs.

- 9. The composition of claim 8, wherein the isolated crystals of compound (1) are present as orthorhombic crystals.
- 10. The composition of claim 8, wherein the isolated crystals of compound (1) exhibit a PXRD pattern substantially as shown for polymorphic Form A in Figure 6.
- 11. The composition of claim 8, wherein the isolated crystals are at least about 90% polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.
- 12. The composition of claim 8, wherein the isolated crystals of compound (1) contain at least about 90% of polymorphic Form A with respect to other polymorphic forms.